Benefits of IL Therapies in Patients with PP

In this discussion among dermatologists, the focus is on the efficacy and safety of various biologics for treating plaque psoriasis, particularly TNF blockers, IL-23 blockers, and IL-17 blockers. The dermatologists express a preference for newer biologics due to their improved dosing schedules, efficacy, and safety profiles compared to TNF blockers. They highlight the benefits of IL-23 blockers, such as infrequent dosing and favorable safety profiles, especially in patients with comorbidities like inflammatory bowel disease. IL-17 blockers are praised for their rapid improvement in psoriasis symptoms, but concerns arise regarding their efficacy in psoriatic arthritis, particularly in cases of axial involvement. The discussion also touches on the importance of preventing radiographic progression in joint disease and the potential implications for treatment selection. Additionally, the dermatologists discuss the different generations of IL-17 blockers and IL-12/23 blockers, noting advancements in dosing schedules to improve treatment outcomes and patient adherence. Overall, the dermatologists emphasize the importance of considering both efficacy and safety when selecting biologic therapies for plaque psoriasis.

Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.